The objectives of the authors were four-fold.
Performance of the screening tests: only studies of women with no clinical symptoms of ovarian cancer were eligible for inclusion. Studies of women already scheduled for surgical investigation were excluded.
Adverse effects of screening: for the assessment of psychological effects of screening, studies in the general population or in women at high risk were eligible for inclusion.
Outcomes assessed in the review
Performance of the screening tests: no inclusion criteria relating to outcome measures were specified. The outcome measures in the review were the calculated sensitivity, specificity, positive predictive value (PPV) and false-positive rates.
Adverse effects of screening: studies were eligible for inclusion if they reported on the surgical complications of procedures used in diagnosing ovarian cancer (such as open or laparoscopic oophorectomy), or on the psychological outcomes of screening. For studies on the adverse effects of surgery, studies of simultaneous oophorectomy and hysterectomy and studies of the long-term effects of oophorectomy were excluded.
How were decisions on the relevance of primary studies made?
For studies evaluating the performance of screening tests, three reviewers independently assessed the retrieved abstracts and titles for relevance; the full versions of selected papers were independently assessed for inclusion by two reviewers.
Assessment of study quality
Methodological quality was assessed based on criteria recommended by the Cochrane Methods Working Group on Systematic Reviews of Screening and Diagnostic Tests (see Other Publications of Related Interest no.1). Information relating to the following methodological issues was recorded: the method and completeness of follow-up of women with a negative screening outcome; the clarity of cut-off points and explicitness of the description of the protocol; the completeness of result reporting, including the drop-out rates at each stage of screening; and the description of the study population with respect to major risk factors. These factors were considered separately in assessing the validity of each study in relation to the different outcomes investigated.
The authors do not state how the papers were assessed for validity, or how many of the reviewers performed the validity assessment.
Data extraction
The data were extracted by one reviewer using a standard data extraction form, and checked by a second reviewer.
Methods of synthesis
How were the studies combined?
The studies were combined in a narrative description.
How were differences between studies investigated?
Differences between the studies were discussed in the text.
Results of the review
Performance of the screening tests: 25 prospective screening studies were included, of which 16 screened women who were at average risk for their age of developing ovarian cancer (i.e. the results may be relevant to the general population). The size of the studies varied between 435 and 22,000 for these general population samples.
Adverse effects of screening: there were 3 studies reporting on the psychological effects of screening and 9 studies reporting on the complications of surgical investigation.
No completed RCTs of screening for ovarian cancer were identified. Approximately 50% (95% confidence interval, CI: 23, 77) and 75% (95% CI: 35, 97) of the patients were diagnosed at Stage I in CA-125-based and ultrasound screening studies, respectively. Annual screening with ultrasound appeared to have a sensitivity or detection rate close to 100%. The reported sensitivity of annual CA-125-based screening was approximately 80%. The false-positive result rate was around 1.2 to 2.5% for women screened by ultrasound scanning, and 0.1 to 0.6% for CA-125-based screening. Approximately 0.5 to 1% of women will suffer a significant complication due to surgery, and most of those who do not have ovarian cancer will have a benign gynaecological condition. The proportion of screened women who are recalled for further testing and assessment, resulting in potential distress and anxiety to otherwise healthy women, is around 3 to 12%.
The impact of screening for ovarian cancer.
The PPVs of ovarian screening were low: 3% for surgery and 0.6% for initial recall for annual ultrasound screening; 15% for surgery and 1% for initial recall for annual CA-125-based screening. This is due mainly to the relatively low prevalence of ovarian cancer. The evidence suggests that ultrasound screening is more sensitive than CA-125-based screening, although the latter may result in fewer false-positives and, hence, a higher PPV. It was suggested that the addition of colour Doppler imaging to ultrasound screening may reduce the false-positive rate; however, variable results have been reported.
Screening a higher-risk population: there was a lack of evidence on whether screening women at higher risk could reduce the mortality of ovarian cancer.
Cost information
It was suggested that the cost of screening a woman with ultrasound is higher than the cost for CA-125 testing followed by ultrasound screening.
